Partner Headlines - MDVN

  1. Stocks: A Soft Jump On Jobs Data; WhiteWave, Boeing, NXP Climb

    IBD
  2. Top Drugmaker Profits Mixed

    IBD
  3. Medivation, Jazz Q1 Reports Miss; Regeneron Beats

    IBD
  4. Four Hot Stocks You'll Want To Keep On Your Radar

    IBD
  5. Nasdaq, S&P 500 Hang Tough; Avago, Akorn Big Earnings Winners

    IBD
  6. Medivation Tops Q4 Views On Strong Xtandi Results

    IBD
  7. Stocks Mixed; United Therapeutics Jumps To New High

    IBD
  8. Market Edges Higher, Unfazed By Weak HP Results

    IBD
  9. Market's Resilience Is Noteworthy; More Breakouts Emerge

    IBD
  10. Earnings Scheduled For February 25, 2015

    Benzinga
  11. Stocks Show Small Losses; Merger Talk Lifts Discovery

    IBD
  12. Stocks Quietly Lower; Domino's, Medivation Break Out

    IBD
  13. Wedbush Weighs in on Medivation Following Phase II TERRAIN Study ...

    GuruFocus
  14. Valeant Agrees To Buy Dendreon's Provenge

    IBD
  15. Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation ...

    GuruFocus
  16. Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically ...

    GuruFocus
  17. J&J Earnings Beat, But Sales, Guidance Miss Estimates

    IBD
  18. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  19. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  20. Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market

    Benzinga
  21. William Blair's Top BioPharmaceutical Stock Picks for Q1 2015

    GuruFocus
  22. Newly Profitable Medivation Riding High On Drug Sales

    IBD
  23. Chip Stocks, Biotechs Lead Another Nasdaq Rally

    IBD
  24. Major Upgrades And Downgrades In Friday's Market Action

    Benzinga
  25. Medivation Hits High After Q3 Earnings Beat

    IBD
  26. Medivation Hits High After Q3 Earnings Beat

    IBD
  27. Medivation and Astellas Announce Phase 3 Study of Enzalutamide ...

    GuruFocus
  28. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD
  29. Consider Medivation for Your Portfolio

    FoxBusiness
  30. Benzinga's Top Downgrades

    Benzinga
  31. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga
  32. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  33. Fast Money Halftime Report Final Trade From September 12

    Benzinga
  34. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  35. Stifel Raises Medivation Inc Price Target

    Benzinga
  36. Stocks Hitting 52-Week Highs

    Benzinga
  37. A Few Reasons Why Investors Should Consider Dendreon for Their ...

    GuruFocus
  38. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD
  39. Benzinga's Volume Movers

    Benzinga
  40. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  41. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  42. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  43. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  44. Benzinga's Top Upgrades

    Benzinga
  45. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  46. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  47. Morning Market Movers

    Benzinga
  48. Stocks To Watch For April 1, 2014

    Benzinga
  49. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  50. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  51. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  52. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  53. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  54. Benzinga's Top #PreMarket Losers

    Benzinga
  55. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  56. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  57. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  58. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  59. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  60. Stocks Hitting 52-Week Highs

    Benzinga
  61. Benzinga's Top #PreMarket Gainers

    Benzinga
  62. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  63. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  64. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  65. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  66. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  67. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  68. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  69. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  70. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  71. Benzinga's Top Initiations

    Benzinga
  72. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  73. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  74. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  75. Medivation Effects 2-for-1 Stock Split

    Benzinga
  76. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  77. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  78. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  79. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  80. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  81. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  82. Stocks Hitting 52-Week Highs

    Benzinga
  83. Health Care Sector Wrap

    FoxBusiness
  84. Four Winning Trades Based on Analyst Calls

    Benzinga
  85. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  86. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  87. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  88. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  89. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  90. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  91. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  92. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  93. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  94. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  95. Will Johnson & Johnson Cure Cancer?

    Benzinga
  96. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  97. Notable Put Options Activity in Medivation

    Benzinga
  98. Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, ...

    GuruFocus
  99. Medivation's Stellar Technical Performance Entices Option Bulls

    SchaeffersResearch
  100. Benzinga's M&A Chatter for Wednesday February 1, 2012

    Benzinga
Trading Center